Lincoln Pharma's 31st AGM Approves Financials, ₹1.80 Dividend, and Key Director Re-appointments
Lincoln Pharma's 31st AGM on September 30, 2025, approved FY25 financial statements, declared a ₹1.80 dividend, and re-appointed key directors including Mr. Mahendra G. Patel as MD, ensuring stable leadership and shareholder returns.
The AGM results confirm the company's financial health, continuity of leadership, and commitment to shareholder returns through dividend declaration. These are generally expected outcomes but contribute to overall company stability and investor sentiment.
All proposed resolutions, including the adoption of financial statements, dividend declaration, and re-appointment of key managerial personnel, were passed with the requisite majority, indicating strong shareholder confidence and stable governance.
Lincoln Pharmaceuticals Limited held its 31st Annual General Meeting (AGM) on Tuesday, September 30, 2025, at 11:00 A.M. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). All resolutions, comprising ordinary and special business, were duly passed by the requisite majority.
Key outcomes of the AGM include: * Adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2025. * Declaration of a final dividend of ₹1.80 (18%) per equity share on 2,00,29,728 fully paid equity shares of ₹10 each for the financial year 2024-25. * Re-appointment of Mr. Ashish Rajanikant Patel and Mr. Rajanikant Gulabdas Patel as Directors, who retired by rotation. * Re-appointment of Mr. Mahendra G. Patel as Managing Director for a period of 5 years, effective from October 01, 2025. * Re-appointment of Mr. Hashmukh I. Patel as Whole Time Director for a period of 5 years, effective from October 01, 2025. * Re-appointment of Mr. Ashish R. Patel as Whole Time Director for a period of 5 years, effective from November 14, 2025. * Re-appointment of Mr. Munjal M. Patel as Whole Time Director for a period of 5 years, effective from November 14, 2025. * Ratification of remuneration for M/s. Kiran J. Mehta & Co., Cost Accountants, for the financial year ending March 31, 2026, at ₹2,50,000 p.a. plus GST and out-of-pocket expenses. * Appointment of M/s. Ankit Sethi & Associates, Company Secretaries, as Secretarial Auditors for a period of 5 consecutive years from FY 2025-26 to FY 2029-30.
Mr. Mahendra Patel, Managing Director, chaired the meeting and provided updates on the company's performance, solar plant, Mehsana plant, and performance in domestic and export markets. The remote e-voting period was from September 26, 2025 (9:00 a.m.) to September 29, 2025 (5:00 p.m.), with e-voting also available during the AGM.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.